Regulation of pulmonary inflammation by leukocytes and extracellular matrix

白细胞和细胞外基质对肺部炎症的调节

基本信息

项目摘要

This Program Project Grant application will test the hypothesis that communication between the stroma tissue-resident cells and infiltrating leukocytes is key to directing lung-specific inflammatory and antiinflammatory responses to infection or injury. We believe that the interplay between these cell populations, mediated by alterations in specific extracellular matrix components, is a critical aspect in the development of the response to challenge. Our overall hypothesis is that changes in local pericellular environments, such as deposition of specific extracellular matrix components or the elaboration of effector molecules, as a consequence of the host response to airway epithelial insults, provide spatial signals for recruitment and activation of leukocytes that ultimately shape the qualitative and quantitative patterns of both the innate and adaptive immune responses. An important, unifying, and novel concept that will be explored in this Program is that the progression from innate to adaptive immunity in the lung is fluid and mechanistically linked. Once recruited, infiltrated leukocytes induce further changes in local environments, escalating the inflammatory response. The individual projects in this proposal will probe different, yet complementary and sequential processes of this proposed inflammatory cascade. These aspects include: (1) the role of the interstitial matrix components versican and hyaluronan in regulating and shaping the innate response to lung infection (Wight), (2) the role ofthe epithelial-derived cytokine TSLP (thymic stromal lymphopoietin) in coordinating innate and adaptive responses in the lung (Ziegler), (3) the role of stromelysin-2 (MMP-10) in controlling macrophage activation during acute infection and later T cell responses (Parks), and (4) the role of the adaptive immune system, particularly regulatory T cells, in controlling chronic infection in the lung (Campbell). Each of these projects shares the common theme of how effectors molecules made by one cell type control the activity of specific leukocytes and overall this Program will provide an integrated approach for examining pulmonary inflammation.
该计划项目资助申请将测试以下假设:基质组织驻留细胞和浸润白细胞之间的通信是指导肺部特异性炎症和炎症反应对感染或损伤的关键。我们认为,这些细胞群之间的相互作用,介导的特定细胞外基质成分的改变,是一个关键方面的发展,对挑战的反应。我们的总体假设是,局部细胞周围环境的变化,如特定细胞外基质成分的沉积或效应分子的产生,作为宿主对气道上皮损伤的反应的结果,为白细胞的募集和激活提供空间信号,最终形成先天性和适应性免疫反应的定性和定量模式。一个重要的,统一的,和新的概念,将在本计划中探讨的是,从先天免疫到适应性免疫在肺部的进展是流体和机械连接。一旦招募,浸润的白细胞诱导局部环境的进一步变化,使炎症反应升级。本提案中的各个项目将探索这一拟议的炎症级联反应的不同但互补和顺序的过程。这些方面包括:(1)间质基质成分多能蛋白聚糖和透明质酸在调节和形成对肺部感染的先天性反应中的作用(Wight),(2)上皮源性细胞因子TSLP的作用(胸腺基质淋巴细胞生成素)在协调肺中的先天性和适应性反应中的作用(齐格勒),(3)溶基质素-2(MMP-10)在控制急性感染期间巨噬细胞活化和随后的T细胞反应中的作用(Parks),以及(4)适应性免疫系统的作用,特别是调节性T细胞在控制肺部慢性感染中的作用(坎贝尔)。这些项目中的每一个都有一个共同的主题,即由一种细胞类型产生的效应分子如何控制特定白细胞的活性,总的来说,该计划将提供一种检查肺部炎症的综合方法。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Steven F Ziegler其他文献

The role of Bcl11b in lineage commitment of CD4+CD8+DP thymocytes via regulation of ThPOK silencer activity
Bcl11b 通过调节 ThPOK 沉默子活性在 CD4 CD8 DP 胸腺细胞谱系定型中的作用
  • DOI:
  • 发表时间:
    2011
  • 期刊:
  • 影响因子:
    0
  • 作者:
    Miyuki Omori-Miyake;Steven F Ziegler;田中宏和
  • 通讯作者:
    田中宏和
Thymic stromal lymphopoietin in normal and pathogenic T cell development and function
胸腺基质淋巴细胞生成素在正常和致病性 T 细胞发育与功能中的作用
  • DOI:
    10.1038/ni1360
  • 发表时间:
    2006-06-19
  • 期刊:
  • 影响因子:
    27.600
  • 作者:
    Steven F Ziegler;Yong-Jun Liu
  • 通讯作者:
    Yong-Jun Liu

Steven F Ziegler的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Steven F Ziegler', 18)}}的其他基金

Foxp3 isoforms and IgE-mediated UVB-induced skin inflammation expression
Foxp3亚型和IgE介导的UVB诱导的皮肤炎症表达
  • 批准号:
    10728256
  • 财政年份:
    2023
  • 资助金额:
    $ 219.33万
  • 项目类别:
Regulation of Tfh function in autoimmunity by TSLP
TSLP 对自身免疫中 Tfh 功能的调节
  • 批准号:
    10441850
  • 财政年份:
    2022
  • 资助金额:
    $ 219.33万
  • 项目类别:
Regulation of Tfh function in autoimmunity by TSLP
TSLP 对自身免疫中 Tfh 功能的调节
  • 批准号:
    10571867
  • 财政年份:
    2022
  • 资助金额:
    $ 219.33万
  • 项目类别:
Foxp3DEx2 isoform expression leads to Treg dysfunction and SLE
Foxp3DEx2 同工型表达导致 Treg 功能障碍和 SLE
  • 批准号:
    10363690
  • 财政年份:
    2021
  • 资助金额:
    $ 219.33万
  • 项目类别:
Epithelial regulation of ECM and leukocyte adhesion in viral-triggered asthma
病毒引发的哮喘中 ECM 和白细胞粘附的上皮调节
  • 批准号:
    10160630
  • 财政年份:
    2020
  • 资助金额:
    $ 219.33万
  • 项目类别:
Epithelial control of responses to allergen challenge and viral exacerbation
上皮细胞对过敏原挑战和病毒恶化反应的控制
  • 批准号:
    10168800
  • 财政年份:
    2020
  • 资助金额:
    $ 219.33万
  • 项目类别:
Epithelial regulation of ECM and leukocyte adhesion in viral-triggered asthma
病毒引发的哮喘中 ECM 和白细胞粘附的上皮调节
  • 批准号:
    10202414
  • 财政年份:
    2020
  • 资助金额:
    $ 219.33万
  • 项目类别:
Generating tolerance to antibody-based drugs
产生对抗体药物的耐受性
  • 批准号:
    9258339
  • 财政年份:
    2017
  • 资助金额:
    $ 219.33万
  • 项目类别:
Epithelial control of responses to allergen challenge and viral exacerbation
上皮细胞对过敏原挑战和病毒恶化反应的控制
  • 批准号:
    9157669
  • 财政年份:
    2016
  • 资助金额:
    $ 219.33万
  • 项目类别:
Epithelial control of responses to allergen challenge and viral exacerbation
上皮细胞对过敏原挑战和病毒恶化反应的控制
  • 批准号:
    9315099
  • 财政年份:
    2016
  • 资助金额:
    $ 219.33万
  • 项目类别:

相似海外基金

Development of small molecule inhibitors as anti-inflammatory agents and antidotes for arsenicals
开发作为抗炎剂和砷解毒剂的小分子抑制剂
  • 批准号:
    10727507
  • 财政年份:
    2023
  • 资助金额:
    $ 219.33万
  • 项目类别:
Discovery of New Anti-Inflammatory Agents to Treat COPD
发现治疗慢性阻塞性肺病的新型抗炎药
  • 批准号:
    9194162
  • 财政年份:
    2016
  • 资助金额:
    $ 219.33万
  • 项目类别:
Synthesis of anti-inflammatory agents and their structure-activity relationships studies
抗炎药的合成及其构效关系研究
  • 批准号:
    496858-2016
  • 财政年份:
    2016
  • 资助金额:
    $ 219.33万
  • 项目类别:
    University Undergraduate Student Research Awards
NAAA Inhibitors as Anti-inflammatory Agents, Phase II
NAAA 抑制剂作为抗炎剂,II 期
  • 批准号:
    9201955
  • 财政年份:
    2015
  • 资助金额:
    $ 219.33万
  • 项目类别:
Novel flavonoids as anti-inflammatory agents in alcoholism
新型黄酮类化合物作为酒精中毒的抗炎剂
  • 批准号:
    8251289
  • 财政年份:
    2014
  • 资助金额:
    $ 219.33万
  • 项目类别:
TLR-7 Agonists as Targeted Anti-inflammatory Agents in Arthritis
TLR-7 激动剂作为关节炎的靶向抗炎药
  • 批准号:
    8302750
  • 财政年份:
    2012
  • 资助金额:
    $ 219.33万
  • 项目类别:
Design and in vivo delivery of novel anti-inflammatory agents
新型抗炎剂的设计和体内递送
  • 批准号:
    267940
  • 财政年份:
    2012
  • 资助金额:
    $ 219.33万
  • 项目类别:
    Operating Grants
Development of inlammasome inhibitors to be used as anti-inflammatory agents
开发用作抗炎剂的inlammasome抑制剂
  • 批准号:
    8403458
  • 财政年份:
    2012
  • 资助金额:
    $ 219.33万
  • 项目类别:
Development of inlammasome inhibitors to be used as anti-inflammatory agents
开发用作抗炎剂的inlammasome抑制剂
  • 批准号:
    8549297
  • 财政年份:
    2012
  • 资助金额:
    $ 219.33万
  • 项目类别:
TLR-7 Agonists as Targeted Anti-inflammatory Agents in Arthritis
TLR-7 激动剂作为关节炎的靶向抗炎药
  • 批准号:
    8472443
  • 财政年份:
    2012
  • 资助金额:
    $ 219.33万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了